Anocca Presents Data at ESMO Congress on Preclinical Development of its TCR-T Cell Therapies for Cancer

SÖDERTÄLJE, SWEDEN, 9 September 2024 – Anocca AB, a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, announces it will present its novel platform approach to therapeutic TCR discovery and preclinical data for its lead TCR-T cell therapy product at the European Society of Medical Oncology (ESMO) Congress 2024.

Category: Investigational Immunology

Poster title: Preclinical development of TCR-modified T-cell therapies against mutated KRAS 

Date and time: 9am-5pm local time on Saturday 14 September

Location: Hall 6, Fira Barcelona Gran Via, Barcelona, Spain

Link: https://tinyurl.com/4n67775y

The poster introduces Anocca’s programmable cellular technology platform that systematically recreates human T-cell biology to map T-cell targets and build TCR libraries for the generation of validated therapeutic TCRs, and describes the preclinical development of its lead therapeutic TCR-T product targeting KRAS-G12V that is being progressed into planned clinical trials. KRAS is the most frequently mutated oncogene and associated with highly fatal cancers of the pancreas, lung and colon. Due to its intrinsic properties, effective targeting strategies have historically been elusive, presenting significant unmet need.

Hugh Salter, Chief Scientific Officer at Anocca, and presenter of the poster, added, "We are excited to present our technology platform and the details of our lead TCR-T product at ESMO. Our research demonstrates that TCR-T cell therapies offer a precise route, via autologous modification of patient CD8 cells, to directly address foundational driver events in solid tumours.”

Members of the company’s management team, including CSO Hugh Salter, CMO Zahid Bashir, Clinical Science